NovoCure Limited
NVCR
$17.96
$0.070.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.91% | 20.54% | 21.81% | 19.28% | 13.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.91% | 20.54% | 21.81% | 19.28% | 13.36% |
| Cost of Revenue | 14.34% | 2.20% | 10.22% | 1.87% | 13.76% |
| Gross Profit | 11.12% | 26.26% | 25.72% | 25.72% | 13.23% |
| SG&A Expenses | 6.15% | 47.67% | 0.08% | -4.95% | 1.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.13% | 25.07% | 0.87% | -2.52% | -1.32% |
| Operating Income | 8.80% | -38.55% | 44.90% | 46.37% | 31.09% |
| Income Before Tax | 4.26% | -43.27% | 55.24% | 57.83% | 38.05% |
| Income Tax Expenses | -43.47% | 25.41% | 611.40% | 202.96% | 259.31% |
| Earnings from Continuing Operations | 11.46% | -40.02% | 38.22% | 41.87% | 26.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.46% | -40.02% | 38.22% | 41.87% | 26.95% |
| EBIT | 8.80% | -38.55% | 44.90% | 46.37% | 31.09% |
| EBITDA | 10.76% | -39.18% | 46.55% | 48.70% | 32.72% |
| EPS Basic | 13.87% | -38.08% | 39.07% | 42.63% | 28.06% |
| Normalized Basic EPS | 6.89% | -37.87% | 55.86% | 56.25% | 38.96% |
| EPS Diluted | 13.87% | -38.10% | 39.07% | 42.61% | 28.06% |
| Normalized Diluted EPS | 6.89% | -37.87% | 55.86% | 56.25% | 38.96% |
| Average Basic Shares Outstanding | 2.81% | 1.39% | 1.38% | 1.33% | 1.51% |
| Average Diluted Shares Outstanding | 2.81% | 1.39% | 1.38% | 1.33% | 1.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |